Source:http://linkedlifedata.com/resource/pubmed/id/21437966
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2011-7-12
|
pubmed:abstractText |
Catabolic inflammatory cytokines are prevalent in osteoarthritis (OA). The purpose of this study was to evaluate an autologous protein solution (APS) as a potential chondroprotective agent for OA therapy. APS was prepared from platelet-rich plasma (PRP). The APS solution contained both anabolic (bFGF, TGF-?1, TGF-?2, EGF, IGF-1, PDGF-AB, PDGF-BB, and VEGF) and anti-inflammatory (IL-1ra, sTNF-RI, sTNF-RII, IL-4, IL-10, IL-13, and IFN?) cytokines but low concentrations of catabolic cytokines (IL-1?, IL-1?, TNF?, IL-6, IL-8, IL-17, and IL-18). Human articular chondrocytes were pre-incubated with the antagonists IL-1ra, sTNF-RI, or APS prior to the addition of recombinant human IL-1? or TNF?. Following exposure to inflammatory cytokines, the levels of MMP-13 in the culture medium were evaluated by ELISA. MMP-13 production stimulated in chondrocytes by IL-1? or TNF? was reduced by rhIL-1ra and sTNF-RI to near basal levels. APS was also capable of inhibiting the production of MMP-13 induced by both IL-1? and TNF?. The combination of anabolic and anti-inflammatory cytokines in the APS created from PRP may render this formulation to be a potential candidate for the treatment of inflammation in patients at early stages of OA.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin 1 Receptor Antagonist...,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1beta,
http://linkedlifedata.com/resource/pubmed/chemical/MMP13 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 13,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1554-527X
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright © 2011 Orthopaedic Research Society.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1320-6
|
pubmed:meshHeading |
pubmed-meshheading:21437966-Blood Proteins,
pubmed-meshheading:21437966-Cartilage, Articular,
pubmed-meshheading:21437966-Cells, Cultured,
pubmed-meshheading:21437966-Chondrocytes,
pubmed-meshheading:21437966-Drug Antagonism,
pubmed-meshheading:21437966-Drug Combinations,
pubmed-meshheading:21437966-Drug Synergism,
pubmed-meshheading:21437966-Humans,
pubmed-meshheading:21437966-Interleukin 1 Receptor Antagonist Protein,
pubmed-meshheading:21437966-Interleukin-1beta,
pubmed-meshheading:21437966-Knee Joint,
pubmed-meshheading:21437966-Matrix Metalloproteinase 13,
pubmed-meshheading:21437966-Platelet-Rich Plasma,
pubmed-meshheading:21437966-Recombinant Proteins,
pubmed-meshheading:21437966-Tumor Necrosis Factor-alpha
|
pubmed:year |
2011
|
pubmed:articleTitle |
Autologous protein solution inhibits MMP-13 production by IL-1? and TNF?-stimulated human articular chondrocytes.
|
pubmed:affiliation |
Biomet Biologics, Warsaw, Indiana. jennifer.woodell-may@biomet.com
|
pubmed:publicationType |
Journal Article
|